(263 days)
No
The summary describes a mechanical hip stem implant and does not mention any software, algorithms, or data processing that would indicate the use of AI/ML.
Yes
The device is a hip stem used in arthroplasty to treat various degenerative joint diseases and fractures, which falls under the definition of a therapeutic device as it directly addresses and aims to alleviate or cure a diseased or abnormal condition in the body.
No
The device description clearly states that the product is a "femoral stem for total or hemi hip arthroplasty," which is an implant used in surgery, not a diagnostic tool.
No
The device description explicitly states that the device is a "femoral stem" made from "titanium alloy with a partial coating of hydroxyapatite (HA)". This is a physical implant, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information for diagnosis, monitoring, or screening.
- Device Description: The description clearly states that the BethaLoc® hip stems are "femoral stems for total or hemi hip arthroplasty." This means they are implanted medical devices used in surgery to replace parts of the hip joint.
- Intended Use: The intended use describes the conditions for which the hip stems are used, all of which relate to musculoskeletal issues requiring surgical intervention and joint replacement.
- Lack of Specimen Analysis: There is no mention of the device being used to analyze any biological specimens.
Therefore, the BethaLoc® hip stems are surgical implants, not IVD devices.
N/A
Intended Use / Indications for Use
The EcoFit®, implaFit® and BethaLoc® hip stems are indicated for use in cases of:
· Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis;
- · Rheumatoid arthritis;
· Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement that are unmanageable by other techniques; and
· Revision of previously failed total hip arthroplasty.
The EcoFit®, implaFit® and BethaLoc® hip stems, when used in conjunction with the ic-Bipolar Heads, are intended for the following indications:
- Non-inflammatory degenerative joint ● disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis ●
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture and ● trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
The EcoFit® hip stems, the implaFit® hip stems cementless and the BethaLoc® hip stems are intended for uncemented, press-fit fixation.
The implaFit® hip stems cemented are intended for cemented fixation.
The ic-Bipolar Head System is intended for uncemented use in hemiarthroplasty, where the femoral head requires replacement but the acetabulum does not, in conjunction with the BethaLoc® hip stems and EcoFit® Hip System for the following indications:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis ●
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture and ● trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
Product codes
LZO, KWY, OQI
Device Description
The purpose of this Traditional 510(k) is introduce into interstate commerce in the United States the BethaLoc® hip stems. The BethaLoc® hip stems are femoral stems for total or hemi hip arthroplasty. The BethaLoc® hip stems are available in standard and lateralized offset configurations.
The BethaLoc® hip stems are monoblock, tapered straight stems made from titanium alloy with a partial coating of hydroxyapatite (HA). They are fixed by press-fitting. The BethaLoc® hip stems are intended to be used with previously cleared EcoFit® Hip components.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Femoral, Acetabulum
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
All necessary testing has been performed for the "worst-case" components of the BethaLoc® hip stems to assure substantial equivalence to its predicates and to demonstrate the subject devices perform as intended. All testing was performed on test units representative of or worst-case compared to the finished device. The following evaluations were conducted to characterize the devices:
• Fatigue Testing (ISO 7206-4 and ISO 7206-6)
. Impingement Testing (ASTM F2582-14)
Taper Disassembly Testing (ASTM F2009) .
Range of Motion (ROM) Evaluation (ISO 21535) ●
Coating Characterization (ASTM F1980, ASTM ● F1609, ASTM F1185, ASTM F1044, ASTM F1147, ASTM F1926, ASTM F1160, ASTM F2024, ISO 13779)
Corrosion and Fretting Fatigue Rationale
Biocompatibility (ISO 10993-1) ●
Cytotoxicity (ISO 10993-5) o
Sensitization (ISO 10993-10) o
O Irritation (ISO 10993-10)
Material-Mediated Pyrogenicity (ISO 10993-11) O
Genotoxicity (ISO 10993-3) O
Chemical Characterization (ISO 10993-18) O
Toxicological Risk Assessment (ISO 10993-17) O
Conclusions: The BethaLoc® hip stems subject to this submission possess the same intended use as and similar technological characteristics to the predicate device system components. All performance testing conducted for the BethaLoc® hip systems met the predetermined acceptance criteria or were otherwise considered acceptable. As such, the BethaLoc® hip stems components are substantially equivalent to the predicate devices for the intended use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K203420, K163577, K180263, K191569
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3353 Hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis.
(a)
Identification. A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
June 20, 2023
implantcast Gmbh % Dave McGurl Vice President, Regulatory Affairs - Orthopedics MCRA, LLC. 803 7th Street NW Third Floor Washington, District of Columbia 20001
Re: K223103
Trade/Device Name: BethaLoc® stem cementless HA Regulation Number: 21 CFR 888.3353 Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis Regulatory Class: Class II Product Code: LZO, KWY, OOI Dated: May 19, 2023 Received: May 19, 2023
Dear Dave McGurl:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Limin Sun -S
Limin Sun, Ph.D. Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name
BethaLoc® stem cementless HA
Indications for Use (Describe)
The EcoFit®, implaFit® and BethaLoc® hip stems are indicated for use in cases of:
· Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis;
- · Rheumatoid arthritis;
· Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement that are unmanageable by other techniques; and
· Revision of previously failed total hip arthroplasty.
The EcoFit®, implaFit® and BethaLoc® hip stems, when used in conjunction with the ic-Bipolar Heads, are intended for the following indications:
· Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis
- · Correction of functional deformity
· Treatment of non-union, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
The EcoFit® hip stems, the implaFit® hip stems cementless and the BethaLoc® hip stems are intended for uncemented, press-fit fixation.
The implaFit® hip stems cemented are intended for cemented fixation.
The ic-Bipolar Head System is intended for uncemented use in hemiarthroplasty, where the femoral head requires replacement but the acetabulum does not, in conjunction with the BethaLoc® hip stems and EcoFit® Hip System for the following indications:
· Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis
- · Correction of functional deformity
· Treatment of non-union, femoral neck fracture and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
3
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(K) SUMMARY
| Manufacturer: | implantcast GmbH
Lueneburger Schanze 26
21614 Buxtehude
Germany |
|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact: | Ms. Juliane Höppner
Phone: +49 4161 744-135
Fax: +49 4161 744-200
j.hoeppner@implantcast.de |
| Prepared By: | Mr. Dave McGurl
MCRA, LLC
803 7th St NW, Floor 3
Washington, DC 20001
dmcgurl@mcra.com |
| Date Prepared: | June 15, 2023 |
| Device Trade Name: | BethaLoc® stem cementless HA |
| Device Class and
Common Name: | Class II, Total Hip Replacement |
| Classification: | 21 CFR 888.3353: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis
21 CFR 888.3390: Hip joint femoral (hemi-hip) metal/polymer cemented or uncemented prosthesis |
| Product Codes: | LZO, KWY, OQI |
| Indications for Use: | The EcoFit®, implaFit® and BethaLoc® hip stems are indicated for use in cases of:
Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis;Rheumatoid arthritis; |
5
- Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement that are unmanageable by other techniques; and
- Revision of previously failed total hip arthroplasty. ●
The EcoFit®, implaFit® and BethaLoc® hip stems, when used in conjunction with the ic-Bipolar Heads, are intended for the following indications:
- Non-inflammatory degenerative joint ● disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis ●
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture and ● trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
The EcoFit® hip stems, the implaFit® hip stems cementless and the BethaLoc® hip stems are intended for uncemented, press-fit fixation.
The implaFit® hip stems cemented are intended for cemented fixation.
The ic-Bipolar Head System is intended for uncemented use in hemiarthroplasty, where the femoral head requires replacement but the acetabulum does not, in conjunction with the BethaLoc® hip stems and EcoFit® Hip System for the following indications:
- Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis
- Rheumatoid arthritis ●
- Correction of functional deformity
- Treatment of non-union, femoral neck fracture and ● trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.
- Device Description: The purpose of this Traditional 510(k) is introduce into interstate commerce in the United States the BethaLoc® hip stems. The BethaLoc® hip stems are femoral stems for total or hemi hip arthroplasty. The BethaLoc® hip stems are available in standard and lateralized offset configurations.
6
| The BethaLoc® hip stems are monoblock, tapered straight stems made from titanium alloy with a partial coating of hydroxyapatite (HA). They are fixed by press-fitting. The BethaLoc® hip stems are intended to be used with previously cleared EcoFit® Hip components. | |
|---|---|
| Predicate Devices: | Primary Predicate: |
| • EcoFit® Hip System (K203420 K163577, K180263, and K191569) | |
| Reference Devices: | |
| • Smith & Nephew, Inc. SL-PLUSTM MIA Femoral Stem with Ti/HA and SL-PLUSTM Femoral Stem with Ti/HA (K122296 and K143096) | |
| • Encore Medical TaperFill™ Femoral Hip Stem (K130099) | |
| Substantial | |
| Equivalence: | The BethaLoc® hip stems are substantially equivalent to the hip stems of the legally marketed predicate device systems, the implantcast EcoFit® Hip System, the Smith & Nephew, Inc. SL-PLUSTM MIA Femoral Stem with Ti/HA and SL-PLUSTM Femoral Stem with Ti/HA, and the Encore Medical TaperFill™ Femoral Hip Stem with respect to intended use and design. There are some differences in stem geometry and dimensions of the BethaLoc® hip stems as compared to the EcoFit® Hip System predicate. These differences include cross-sectional geometry, head/neck angle, stem length, neck length, and offset length. These differences do not raise new questions of safety and effectiveness. |
| Performance Testing: | All necessary testing has been performed for the "worst-case" components of the BethaLoc® hip stems to assure substantial equivalence to its predicates and to demonstrate the subject devices perform as intended. All testing was performed on test units representative of or worst-case compared to the finished device. The following evaluations were conducted to characterize the devices: |
| • Fatigue Testing (ISO 7206-4 and ISO 7206-6) |
- . Impingement Testing (ASTM F2582-14)
7
- Taper Disassembly Testing (ASTM F2009) .
- Range of Motion (ROM) Evaluation (ISO 21535) ●
- Coating Characterization (ASTM F1980, ASTM ● F1609, ASTM F1185, ASTM F1044, ASTM F1147, ASTM F1926, ASTM F1160, ASTM F2024, ISO 13779)
- Corrosion and Fretting Fatigue Rationale
- Biocompatibility (ISO 10993-1) ●
- Cytotoxicity (ISO 10993-5) o
- Sensitization (ISO 10993-10) o
- O Irritation (ISO 10993-10)
- Material-Mediated Pyrogenicity (ISO 10993-11) O
- Genotoxicity (ISO 10993-3) O
- Chemical Characterization (ISO 10993-18) O
- Toxicological Risk Assessment (ISO 10993-17) O
- The BethaLoc® hip stems subject to this submission possess Conclusions: the same intended use as and similar technological characteristics to the predicate device system components. All performance testing conducted for the BethaLoc® hip systems met the predetermined acceptance criteria or were otherwise considered acceptable. As such, the BethaLoc® hip stems components are substantially equivalent to the predicate devices for the intended use.